[1] |
Tomiyama H,Takata Y,Shiina K, et al.Concomitant existence and interaction of cardiovascular abnormalities in obstructive sleep apnea subjects with normal clinic blood pressure[J]. Hypertens Res, 2009, 32(3): 201-206.
|
[2] |
周琦,余振球. 原发性高血压伴阻塞性睡眠呼吸暂停低通气综合征对左心室结构的影响[J]. 心肺血管杂志, 2012, 31(6): 681-686.
|
[3] |
严治涛,程维平,毕云, 等. 高血压合并阻塞性睡眠呼吸暂停低通气综合征患者左心室结构与收缩功能的影响因素[J]. 中华高血压杂志, 2011, 19(3): 273-277.
|
[4] |
Manica G,Fagard R,Narkiewicz K, et al.2013 ESH/ESC guideline for the management of arterial hypertention: the task force for the management of arterial hypertention of European Society of Heypertention (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2013, 34(28): 2159-2219.
|
[5] |
中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011, 19(8): 701-743.
|
[6] |
中华医学会呼吸病学分会, 睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J]. 柳州医学, 2012, 35(3): 162-165.
|
[7] |
Parati G,Lombardi C,Hedner J, et al.Position paper on themanagement of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by themembers of European COST (Cooperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea[J]. J Hypertens, 2012, 30(4): 633-646.
|
[8] |
Goodfriend TL,Calhoun DA.Resistant hypertension, obesity, sleepapnea, and aldosterone: theory and therapy[J]. Hypertension, 2004, 43(3) : 518-524.
|
[9] |
徐新献,姚武位,周婧, 等. 不同年龄段老年高血压病患者动态血压及血压昼夜节律的变化特征[J/CD]. 中华诊断学电子杂志, 2016, 4(1): 56-58.
|
[10] |
陈宝元. 睡眠呼吸暂停相关性高血压的诊断和治疗[J]. 中国实用内科杂志, 2010, 30(4): 306-308.
|
[11] |
李南方,王磊,周克明, 等. 新疆维吾尔自治区人民医院住院高血压患者病因构成特点[J]. 中华心血管病杂志, 2007, 35(9): 865-868.
|
[12] |
曾文,张广宇. 血管紧张素转化酶基因多态性与肾疾病ACEI的治疗[J]. 国外医学(遗传学分册), 2000, 23(1): 16-19.
|
[13] |
Cox R,Bouzekri N,Martin S, et al.Angiotemin-1-converting enzyme(ACE) plasma concentration is influence by multiple ACE-linked quantitative trait nucleotides[J]. Hum Mol Genot, 2012, 11(23): 2969-2977.
|
[14] |
Iwai N,Ohmichi N,Nakamura Y, et al.DD genotype of the angiotensin-converting enzyme is a risk factor for left ventricular hypertrophy [J]. Circulation, 1994, 90(6): 2622-2628.
|
[15] |
Shlyakhto EV,Shwartz EI,Nefedova YB, et al.Lack of association of the renin-angiotensin system genes polymorphisms and left ventricular hypertrophy in hypertension[J]. Blood Press, 2001, 10(3): 135-141.
|
[16] |
Kato N,Tatara Y,Ohishi M, et al.Angiotensin-converting enzyme single nucleotide polymorphism is a genetic risk factor for cardiovascular disease:a cohort study of hypertensive patients[J]. Hypertens Res, 2011, 34(6): 728-734.
|
[17] |
López-Contreras J,Blanco-Vaca F,Borrás X, et al.Usefulness of the I/D angiotensin-converting enzyme genotype for detecting the risk of left ventricular hypertrophy in pharmacologically treated hypertensive men[J]. J Hum Hypertens, 2000, 14(5): 327-331.
|
[18] |
Bahramali E,Rajabi M,Jamshidi J, et al.Association of ACE gene D polymorphism with left ventricular hypertrophy in patients with diastolic heart failure:a case control study[J]. BMJ open, 2016, 6(2): e010282.
|
[19] |
Schunkert H,Hense HW,Holmer SR, et al.Association between a deletion polymorphism of the angiotensin-converting-enzyme and left ventricular hypertrophy[J]. N Engl J Med, 1994, 330(23): 1634-1638.
|
[20] |
Li X,Li Y,Jia N, et al.Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis[J]. Mol Biol Rep, 2012, 39(12): 10063-10075.
|
[21] |
Danser AH,Schalekamp MA,Bax WA, et al.Angiotensin-converting enzyme in the human heart.Effect of the deletion/insertion polymorphism[J]. Circulaition, 1995, 92(6): 1387-1388.
|